Navigation Links
New Stem Cell Technology to Improve Drug Safety
Date:4/22/2009

TOKYO, April 22 /PRNewswire-Asia/ -- Drug side effects are a major problem for the drug industry. Even very rare events, if serious enough, can warrant drug withdrawal. Unfortunately, these problems often emerge only after a drug has been used by thousands or even millions of patients.

Identifying drugs that can trigger heart attacks before they reach the clinic is a major focus of ReproCELL. Current cardiotoxicity tests, especially at early stages of drug development, tend to focus on one aspect of heart cell function -- the hERG ion channel. But there are a whole range of other ion channels, as well as other possible issues, which hERG tests miss. ReproCELL has developed the QTempo assay to comprehensively screen cardiac ion channels and other factors to significantly reduce the chances of a cardiotoxic drug reaching the clinic.

The QTempo test uses beating heart cells grown in a dish from stem cells. Similar to an ECG, these cells are attached to electrodes to measure their electrical activity, which is monitored as experimental drugs are added. Until recently, ethical issues surrounding human embryonic stem cells, had restricted QTempo to monkey heart cells. Now, under a license agreement between ReproCELL and iPS Academia, a human version of this new test is available. This is the first ever commercial test using iPS technology.

ReproCELL's CEO, Chikafumi Yokoyama, commented "Drug companies usually prefer to see in-vitro data from human cells. Basing the QTempo assay around human heart cells makes the test more clinically relevant. Not only will the improved test contribute to patient safety, it will help reduce the huge amounts of effort drug companies waste on developing drugs that are later withdrawn".

iPS Academia, KYOTO, JAPAN, was established to license iPS technology developed in the Kyoto lab of Shinya Yamanaka. The iPS (induced Pluripotent stem cell) technology is a revolutionary new way of making embryonic-like stem cells from normal adult tissue, typically skin cells.

ReproCELL, TOKYO, JAPAN, offers stem cell-focused products and services to researchers and health professionals. ReproCELL products are used in many of the world's leading stem cell labs and were used in the development of the world's first human iPS cells. ReproCELL has applied its stem cell expertise to develop pre-clinical and clinical diagnostic tests to improve the development of drugs and monitoring of patients.

For further information, please visit http://www.reprocell.net .


'/>"/>
SOURCE ReproCELL Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Quantum light beams good for fast technology
2. New Smart Technology Makes Patient Data Collection Easier, More Efficient
3. Align Technology Executive to Present at Upcoming Financial Conferences
4. Pioneer Surgical Technology Hires Vice President of New Business Development
5. Purdue researchers develop technology to detect cancer by scanning surface veins
6. Creative Technology Services Enhances its Global Competitiveness with Additional Regulatory Certifications
7. University of Wisconsin Hospitals and Clinics Complete System-Wide Conversion to Masimo SET Pulse Oximetry Technology
8. Patent Reform Legislation Threatens Americas Leadership in Medical Technology Innovation
9. Stevens Health, Technology and Society roundtable: Sept. 19
10. Microbiotic technology developed for microinjection of zebrafish embryos
11. Proven Terumo Coronary Guidewire Technology Is Now Available in the United States
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... ... health policy issues and applications at AcademyHealth’s Annual Research Meeting June 26-28, 2016, ... work on several important health care topics including advance care planning, healthcare costs ...
(Date:6/25/2016)... ... 2016 , ... As a lifelong Southern Californian, Dr. Omkar Marathe earned his ... David Geffen School of Medicine at UCLA. He trained in Internal Medicine at Scripps ... in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where he had the opportunity to ...
(Date:6/24/2016)... ... 2016 , ... Those who have experienced traumatic events may suffer from a ... such as drug or alcohol abuse, as a coping mechanism. To avoid this pain ... following a traumatic event. , Trauma sufferers tend to feel a range of emotions, ...
(Date:6/24/2016)... San Francisco, CA (PRWEB) , ... June 24, ... ... at CitiDent, is now offering micro-osteoperforation for accelerated orthodontic treatment. Dr. Cheng has ... , self-ligating Damon brackets , AcceleDent, and accelerated osteogenic orthodontics. , ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... ... Living, is proud to recognize Dr. Barry M. Weintraub as a prominent plastic ... most beautiful women in the world, and the most handsome men, look naturally ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... Tenn. , June 24, 2016  Arkis ... providing less invasive and more durable cerebrospinal fluid ... in funding.  The Series-A funding is led by ... Lighthouse Fund, and other private investors.  Arkis, new ... neurosurgical instrumentation and the market release of its ...
(Date:6/23/2016)... , June 23, 2016 Any dentist who has ... of the current process. Many of them do not even ... technical difficulties and high laboratory costs involved. And those who ... it at such a high cost that the majority of ... Dr. Parsa Zadeh , founder of Dental Evolutions ...
(Date:6/23/2016)... Roche (SIX: RO, ROG; OTCQX: RHHBY) announced ... BRAHMS PCT (procalcitonin) assay as a dedicated testing solution ... this clearance, Roche is the first IVD company in ... sepsis risk assessment and management. PCT is ... levels in blood can aid clinicians in assessing the ...
Breaking Medicine Technology: